
ADHD Medication That Won't Worsen Anxiety in Adults
Finding the right ADHD medication can be a challenge—especially for adults who also struggle with anxiety. Many traditional stimulant medications for ADHD are known to potentially increase anxiety symptoms. This dual diagnosis requires a more careful approach to treatment. The good news is that there are ADHD medications and strategies that help improve focus without making anxiety worse. In fact, some can help manage both conditions simultaneously. In this blog, we explore options that can treat best adhd medication for adults with anxiety while minimizing or avoiding anxiety-related side effects.
When it comes to managing anxiety or depression, selecting the right medication can make a significant difference in treatment outcomes. Both medications work by increasing serotonin levels in the brain, but they can affect individuals differently. The decision between Zoloft vs Lexapro often depends on personal response, side effect profiles, and specific symptoms. While one may cause more sleep-related side effects, the other might impact sexual function or appetite more noticeably. Consulting with a healthcare provider is essential to evaluate which option aligns best with your mental health needs and overall lifestyle for long-term wellness.
ADHD and anxiety disorders frequently occur together in adults. In fact, studies suggest that up to 50% of adults with ADHD may also experience an anxiety disorder. While ADHD affects attention, impulsivity, and executive functioning, anxiety involves excessive worry, restlessness, and tension. The two conditions can worsen each other. For example, ADHD-related forgetfulness or disorganization can lead to stressful situations, which may then trigger anxiety. Conversely, anxiety can make it harder to focus, which mimics or exacerbates ADHD symptoms.
Because of this overlap, choosing the right medication requires a treatment plan that targets ADHD symptoms without aggravating anxiety. It's important to remember that everyone responds differently to medications, so what works for one person may not work for another.
Stimulants like Adderall (amphetamine/dextroamphetamine) and Ritalin (methylphenidate) are among the most commonly prescribed ADHD medications. While effective for increasing focus and reducing impulsivity, they can cause side effects such as increased heart rate, jitteriness, and insomnia—all of which can worsen anxiety. Adults with co-occurring anxiety disorders often find stimulants make them feel on edge, restless, or overly alert.
This does not mean stimulants are never an option, but it does mean that people with anxiety need to be especially cautious. Low-dose strategies, extended-release formulations, or non-stimulant alternatives may be more appropriate in these cases.
For adults concerned about anxiety, non-stimulant medications can be a better fit. These options tend to have a more calming effect and are less likely to cause symptoms of anxiousness.
Atomoxetine is a non-stimulant ADHD medication that works by increasing norepinephrine levels in the brain. It's FDA-approved for ADHD in both children and adults. One of the key benefits of Atomoxetine is that it does not typically increase anxiety—in some cases, it may even help reduce it. Because it is not a stimulant, it doesn't cause the same spikes in energy or restlessness that can trigger anxiety. It also has a lower risk of abuse or dependence, making it a safer long-term option for many adults.
Guanfacine is another non-stimulant often used off-label for adult ADHD. Originally developed to treat high blood pressure, Guanfacine works on receptors in the brain to help regulate attention, behavior, and emotional responses. It is known for its calming effect and is often helpful for individuals with hyperactivity, impulsivity, and anxiety. The extended-release version, Intuniv, is designed to provide steady symptom control without significant mood disturbance.
Like Guanfacine, Clonidine is a medication that can calm hyperactive behavior while also helping with sleep and anxiety. Although more often used in children, some adults benefit from Clonidine as part of their ADHD treatment plan. It can be especially useful at night for those who struggle with insomnia due to either ADHD or anxiety.
Bupropion is an atypical antidepressant that is sometimes prescribed off-label for ADHD. It works by influencing dopamine and norepinephrine—two neurotransmitters linked to focus and attention. Bupropion can improve ADHD symptoms and also help with depression. However, its impact on anxiety varies by individual. While some people feel more calm and focused, others may experience a mild increase in anxiety, especially at higher doses. It is best used cautiously in people with high anxiety levels.
Treating ADHD in adults with anxiety is not a one-size-fits-all process. The key is to personalize the approach based on symptom patterns, tolerance for side effects, and overall mental health history. For some, a low-dose stimulant may be effective when combined with therapy or anti-anxiety techniques. For others, non-stimulants may provide more stable results with fewer mental side effects.
Collaboration with a knowledgeable psychiatrist or primary care doctor is crucial. They can help assess the best starting point, monitor reactions to medication, and make adjustments as needed. Keeping track of how you feel—both mentally and physically—can also help guide these decisions.
Medication alone is rarely the full solution. Cognitive behavioral therapy (CBT) can be particularly effective for adults dealing with both ADHD and anxiety. CBT helps individuals develop coping strategies for managing distractions, negative thinking, and stress. Mindfulness practices, regular exercise, good sleep hygiene, and structured routines also help regulate both attention and anxiety.
Lifestyle changes often complement medication by reducing the intensity of symptoms and improving overall functioning. For example, reducing caffeine and alcohol intake can make a significant difference in anxiety levels. Setting up reminders, calendars, and visual cues can support ADHD management without increasing pressure or stress.
Adults with both ADHD and anxiety face a unique challenge when it comes to medication. While stimulants are effective for many, they can worsen anxiety in sensitive individuals. Fortunately, several non-stimulant options—like Atomoxetine, Guanfacine, Clonidine, and Bupropion—offer alternatives that may better balance focus and emotional calm. The key is working closely with a healthcare provider, staying informed, and being open to gradual adjustments. With the right approach, it's entirely possible to manage ADHD effectively without sacrificing peace of mind.
TIME BUSINESS NEWS

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Upturn
a day ago
- Business Upturn
Pliant Therapeutics Provides Update on BEACON-IPF
Bexotegrast development in IPF discontinued Clinical oncology program and early-stage programs continue Recent workforce and operational changes align with next steps SOUTH SAN FRANCISCO, Calif., June 27, 2025 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following the review of data from the recently terminated BEACON-IPF Phase 2b/3 clinical trial, the Company has discontinued development of bexotegrast in idiopathic pulmonary fibrosis (IPF). BEACON-IPF Trial Update BEACON-IPF was a randomized, double-blind, placebo-controlled, global Phase 2b/3 clinical trial evaluating patients with IPF. In March of this year, Pliant announced the voluntary discontinuation of BEACON-IPF following a prespecified data review and recommendation by the trial's independent Data Safety Monitoring Board (DSMB), as well as a secondary review and recommendation by an outside expert panel, citing an imbalance in IPF-related adverse events. Following an analysis of the full safety and efficacy data from the BEACON-IPF trial, the Company is discontinuing development of bexotegrast in IPF. Results showed that at doses of 160 mg and 320 mg, bexotegrast demonstrated an unfavorable risk-benefit profile. Compared to placebo, bexotegrast-treated participants showed an increased risk of experiencing adverse events associated with IPF disease progression, defined as events of worsening of IPF and acute IPF exacerbation, respiratory-related hospitalization, and/or all-cause mortality. The average time to disease progression for bexotegrast-treated participants was 33 weeks, suggesting that the safety risk may not be apparent with shorter dosing duration as was the case in the prior INTEGRIS-IPF Phase 2a trial. At Week 12, bexotegrast 160 mg and 320 mg treatment groups demonstrated improvements in forced vital capacity (FVC) decline of 72 mL (p<0.05) and 46 mL (p>0.05), respectively, compared to placebo. At Week 24, bexotegrast 160 mg and 320 mg treatment groups demonstrated improvements in FVC decline of 58 mL (p>0.05) and 8 mL (p>0.05), respectively, compared to placebo. The full results from BEACON-IPF will be submitted for future publication. 'Although the decision to discontinue bexotegrast in IPF is disappointing for us and the many patients in need of new treatment options, we believe it is the right decision to protect patient safety,' said Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant. 'We sincerely thank all patients, their caregivers, the study investigators and their research teams who were part of the BEACON-IPF clinical program for their extensive efforts.' Oncology Phase 1 Enrollment Continues PLN-101095 is an oral, small molecule, dual selective inhibitor of αvβ8 and αvβ1 integrins, designed to block TGF-β activation in the tumor microenvironment. PLN-101095 is currently undergoing a Phase 1 open-label trial as monotherapy and in combination with pembrolizumab in patients with solid tumors that are resistant to immune checkpoint inhibitors. In March, the Company announced interim results from this trial showing that PLN-101095 was generally well tolerated with confirmed partial responses in 50% of patients at highest dose tested to date, across multiple tumor types. The trial is currently enrolling the fifth of five planned dose cohorts. Early Programs Supported by Proprietary Platform The Company's drug discovery platform consists of a proprietary library of over 15,000 integrin binding molecules, a comprehensive screening assay system (binding, integrin confirmation, ligand-induced internalization) and an advanced live human tissue program. The Company believes in the broad applicability of the platform across multiple disease areas including delivery of drug payloads to cells utilizing integrin receptor-binding molecules as tissue-specific delivery and internalization mechanisms. About Pliant Therapeutics, Inc. Pliant Therapeutics is a clinical-stage biopharmaceutical company and leader in the discovery and development of integrin-based therapeutics. Pliant is conducting a Phase 1 study for PLN-101095, a small molecule, dual-selective inhibitor of α v ß 8 and α v ß 1 integrins, that is being developed for the treatment of solid tumors. In addition, Pliant has received regulatory clearance for the conduct of a Phase 1 study of PLN-101325, a monoclonal antibody agonist of integrin α 7 β 1 targeting muscular dystrophies. Pliant's early-stage platform includes preclinical research focused on tissue-specific delivery and internalization of drug payloads utilizing integrin receptor-binding molecules. For additional information, please visit: Follow us on social media X, LinkedIn and Facebook. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 'may,' 'will,' 'expect,' 'anticipate,' 'estimate,' 'intend,' and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These statements include those regarding development plans for PLN-101095, PLN-101325 and the Company's proprietary platform; and the Company's efforts to align its workforce and operations for its next steps. Because such statements deal with future events and are based on our current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Pliant Therapeutics could differ materially from those described in or implied by the statements in this press release. These forward-looking statements are subject to risks and uncertainties, including those related to the development and commercialization of our product candidates, including any delays in our ongoing or planned preclinical or clinical trials, the impact of current macroeconomic, geopolitical and marketplace conditions on our business, operations, clinical supply and plans, our reliance on single-source third parties located in foreign jurisdictions, including China, for critical aspects of our development operations, the risks inherent in the drug development process, the risks regarding the accuracy of our estimates of expenses and timing of development, our capital requirements and the need for additional financing, including the availability of additional term loans under our loan facility, and our ability to obtain and maintain intellectual property protection for our product candidates. These and additional risks are discussed in the sections titled 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' in our Quarterly Report on Form 10-Q for the period ended March 31, 2025 which are available on the SEC's website at Unless otherwise noted, Pliant is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. Investor and Media Contact: Christopher KeenanVice President, Investor Relations and Corporate CommunicationsPliant Therapeutics, Inc. [email protected]


Time Business News
2 days ago
- Time Business News
How Fast Does Zoloft vs Lexapro Start Working?
When it comes to treating depression and anxiety disorders, selective serotonin reuptake inhibitors (SSRIs) like Zoloft (sertraline) and Lexapro (escitalopram) are among the most commonly prescribed medications. Both are effective, but many patients and providers wonder: how fast does zoloft vs lexapro start working? Understanding the onset of action for these medications is important when managing expectations and treatment plans. While both drugs work similarly by increasing serotonin levels in the brain, their speed of effectiveness can vary slightly depending on individual factors. Managing both ADHD and anxiety in adults requires a thoughtful approach to medication. Stimulants like Vyvanse and non-stimulants such as Strattera are often prescribed, but finding the right fit depends on individual needs and medical history. Some adults may benefit from medications that also have anti-anxiety properties, like certain antidepressants or guanfacine. The best ADHD medication for adults with anxiety balances focus and calm without worsening symptoms. Consulting a healthcare provider is essential to tailor treatment effectively, ensuring both conditions are addressed safely. Personalized plans often lead to better outcomes and improved quality of life. Zoloft and Lexapro belong to the SSRI class of antidepressants, which function by increasing the amount of serotonin available in the brain. Serotonin is a neurotransmitter associated with mood regulation, sleep, and anxiety. By blocking the reabsorption (reuptake) of serotonin into neurons, SSRIs help stabilize mood and reduce symptoms of anxiety and depression. However, the physiological changes they initiate in the brain take time, meaning these medications do not work instantly. Zoloft, the brand name for sertraline, is commonly prescribed for major depressive disorder (MDD), generalized anxiety disorder (GAD), panic disorder, social anxiety disorder, and obsessive-compulsive disorder (OCD). After beginning treatment, some patients report mild improvements—such as reduced anxiety or improved sleep—within the first one to two weeks. However, these early benefits are usually subtle. The full therapeutic effects of Zoloft often take 4 to 6 weeks to become evident. In cases of OCD or more severe depression, it may take up to 8 weeks or longer. The timeline may be influenced by factors such as dosage, consistency of use, individual metabolism, and whether the patient is taking other medications. It's crucial to continue taking Zoloft as prescribed, even if benefits are not immediately noticeable. Lexapro, or escitalopram, is also widely used for depression and anxiety disorders. It is generally considered one of the more tolerable SSRIs, with a slightly quicker onset for some users. Many patients report feeling some improvement within 1 to 2 weeks, particularly with anxiety symptoms. This early response may include reduced nervousness, better sleep, and improved energy. Like Zoloft, the full antidepressant effects of Lexapro may take 4 to 6 weeks. However, some research and patient reports suggest that Lexapro may reach peak effectiveness slightly faster in certain individuals compared to Zoloft. For anxiety in particular, Lexapro may offer more rapid relief, making it a preferred first-line treatment in some clinical settings. While both medications share a similar overall timeline, Lexapro may begin relieving anxiety symptoms a bit sooner for some people. This difference is not always dramatic, but in cases where early symptom control is critical, Lexapro may be preferred. Zoloft might take slightly longer to kick in, especially for mood-related symptoms, but it may be more effective in treating a broader range of conditions such as OCD and PTSD. Lexapro, on the other hand, is generally favored for anxiety and has a more favorable side effect profile for many users. Several factors can impact how quickly a person feels the effects of Zoloft or Lexapro: Individual biology: Genetic makeup, brain chemistry, and metabolism affect how a person responds to medication. Genetic makeup, brain chemistry, and metabolism affect how a person responds to medication. Dosage: Starting doses are often low and gradually increased, which can delay noticeable effects. Starting doses are often low and gradually increased, which can delay noticeable effects. Consistency: Taking medication at the same time each day helps maintain stable levels in the bloodstream. Taking medication at the same time each day helps maintain stable levels in the bloodstream. Other medications or conditions: Interactions with other drugs or underlying health issues can slow down or speed up effectiveness. Interactions with other drugs or underlying health issues can slow down or speed up effectiveness. Lifestyle: Sleep, diet, exercise, and substance use can all influence how well SSRIs work. It is common for patients to feel frustrated while waiting for SSRIs like Zoloft or Lexapro to take full effect. During the initial weeks of treatment, it's important to focus on incremental improvements. These might include better sleep, reduced irritability, or slightly improved concentration. Regular follow-ups with a healthcare provider can help track progress and determine if dose adjustments or medication changes are needed. Sometimes, initial side effects—such as nausea, headaches, or increased anxiety—may appear before improvement sets in. These effects often resolve within a few weeks. Patients are encouraged to communicate openly with their doctors and not to stop taking the medication abruptly, as this may cause withdrawal symptoms or worsen the condition. The decision between Zoloft and Lexapro should be made in consultation with a healthcare provider. If quick relief from anxiety is the priority, Lexapro may offer a slightly faster onset. If the individual has symptoms of OCD or PTSD, Zoloft might be the better option. Both medications are generally well-tolerated and highly effective, but the best choice will depend on the individual's symptoms, medical history, and response to treatment. Both Zoloft and Lexapro are effective SSRIs, but their onset of action can vary slightly depending on individual factors. Lexapro may begin to ease anxiety symptoms within the first 1 to 2 weeks for some users, while Zoloft's benefits might take a bit longer to emerge, particularly for depression. Regardless of which medication is prescribed, it's important to be patient and consistent with treatment. With the right support and follow-up, both medications can offer significant improvements in mood, anxiety, and overall quality of life. TIME BUSINESS NEWS

2 days ago
Impact of cannabis use on male fertility
Dr. Alok Patel answers viewer questions about male fertility, the positives of a short nap during the day and a new study on ADHD medications.